Seattle company founded by Nobel Prize winner plans human tests for experimental COVID-19 drug
Seattle biotech company Cocrystal Pharma received permission from regulators to begin early-stage clinical trials for its COVID-19 and norovirus treatments.
Previously, the company focused on developing treatments for influenza A and B and hepatitis C; during the COVID-19 pandemic, Cocrystal shifted its priorities to COVID-19 and norovirus research.
The company will hold a phase one trial in Australia for a compound intended to fight norovirus and COVID-19; if successful, Cocrystal will move into individual phase two trials to test each virus’ response.
The company is co-led by CEOs Sam Lee and James Martin.